Amina Ammar: Evaluating Rivaroxaban Dosing Alignment Across Cockcroft–Gault and eGFR Equations
Amina Ammar, Clinical Pharmacist at Henry Ford Wyandotte Hospital, shared a post on LinkedIn about a recent article she and her colleagues co-authered, published in Journal of Thrombosis and Thrombolysis, adding:
“Excited to share our latest publication in the Journal of Thrombosis and Thrombolysis!
Our study used data from the Michigan Anticoagulation Quality Improvement Initiative (MAQI²) Registry to evaluate differences in rivaroxaban dosing based on the method used to estimate renal function.
Grateful to everyone who contributed to this work! ”
Title: Disagreement in rivaroxaban dosing between Cockcroft–Gault and eGFR equations in nonvalvular atrial fibrillation
Authors: Amina Ammar, Stephanie Edwin, Geoffrey D. Barnes, Scott Kaatz, Deborah DeCamillo, Xiaowen Kong, Brian Haymart, Noelle Ryan, Christopher Giuliano
Stay updated with Hemostasis Today.
-
Nov 8, 2026, 19:31Anna Kajaste-Rudnitski: Presenting AAV-Induced p53 Signalling in Human CNS Cells at ESGCT 26
-
Nov 8, 2026, 19:29David McIntosh: Cybersecurity Matters, but Blood Availability Remains the Bigger Challenge
-
Nov 8, 2026, 19:26Wenxue Ma: An Integrative Framework for Macrophage-Mediated Therapeutic Resistance in Cancer
-
Nov 8, 2026, 19:25Yildiz Yigit: Presenting a Polycythemia Vera Case at the MPN Subcommittee Session
-
Nov 8, 2026, 18:56Denis Oduor: Strengthening the Regulation and Delivery of Blood Transfusion and Transplantation Services
-
Nov 8, 2026, 18:28Raghavendra Rao: A Narrative Review on Chronic Venous Disease during Pregnancy
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause
-
Nov 8, 2026, 17:38Nasrin Samadi: Can a Normal Clotting Test Be Misleading?